Kadmon

Former Kadmon consultant pleads guilty to insider trading ahead of Sanofi buyout
Fierce Pharma
Wed, 08/24/22 - 10:42 am
Sanofi
Kadmon
insider trading
legal
DOJ
Sanofi's latest analysis of Rezurock can inform future research, company says
Fierce Pharma
Thu, 04/21/22 - 10:34 am
Sanofi
Kadmon
M&A
graft vs host disease
Rezurock
Sanofi cuts 2 dozen Kadmon staffers after $1.9B buyout: filing
Fierce Pharma
Wed, 04/6/22 - 12:26 pm
Sanofi
Kadmon
layoffs
The top 10 biopharma M&A deals in 2021
Fierce Pharma
Tue, 01/18/22 - 10:53 am
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug
Stat
Wed, 09/8/21 - 12:01 pm
Sanofi
Kadmon
M&A
transplant medicine
graft vs host disease
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
Mon, 08/23/21 - 11:10 am
FDA
Cara Therapeutics
Vifor Pharma
Korsuva
Kadmon
belumosudil
Bristol Myers Squibb
Opdivo
Merck
Eisai
Keytruda
Kadmon's Rezurock scores surprise FDA nod in chronic graft-versus-host-disease
Fierce Pharma
Mon, 07/19/21 - 11:04 am
Kadmon
Rezurock
graft vs host disease
FDA
belumodsil
FDA delays Kadmon’s priority review as apparent clampdown continues
Endpoints
Thu, 03/11/21 - 10:40 am
Kadmon
FDA
priority review
belumodsil
graft vs host disease
Kadmon’s graft-versus-host disease med on track for 2020 filing
Fierce Biotech
Thu, 05/21/20 - 11:21 pm
Kadmon
belumodsil
graft vs host disease
clinical trials
Kadmon drops detailed look at cGVHD data; analysts see 'underappreciated potential'
Fierce Biotech
Mon, 02/24/20 - 10:45 am
Kadmon
KD025
cGVHD
clinical trials
Upcoming events – key tests approach for Kadmon and Surface
EP Vantage
Fri, 11/1/19 - 06:53 pm
Kadmon
graft vs host disease
Surface Oncology
SRF373/NZV930
Rough public start for biotech founded by ex-con, as CEO fumes at ‘vicious’ press
Stat
Wed, 07/27/16 - 02:49 pm
Kadmon
Sam Waksal
ImClone
Banned ImClone founder plans IPO for new venture
CNBC
Wed, 09/24/14 - 07:56 am
ImClone
Sam Waksal
IPOs
Kadmon
Sam Waksal, A Hepatitis C Medicine And An FDA Warning Letter
Pharmalot
Fri, 11/22/13 - 10:28 am
hepatitis C
FDA
Ribasphere
Kadmon
ImClone’s Waksal Back in Biotech With Plans for Spinouts
Bloomberg
Tue, 09/3/13 - 10:45 am
ImClone
Sam Waksal
biotech
Kadmon
ImClone Founder Waksal Forming New Biotech Venture
TheStreet.com
Tue, 02/16/10 - 10:40 am
insider trading
ImClone
Kadmon